Bria-PROS+ Clears IND Review for Prostate Cancer

Company: BriaCell Therapeutics · Event Type: Regulatory Clearance (IND) · Modality: HLA-Matched, Off-the-Shelf Cell-Based Immunotherapy · Asset: Bria-PROS+ · Indication: Advanced/Metastatic Prostate Cancer Summary The U.S. Food and Drug Administration issued a Study May Proceed letter for Bria-PROS+, allowing BriaCell Therapeutics to initiate a Phase…